Carbonic anhydrase inhibitors (CAIs) have been a particularly hot topic recently, with a comprehensive review of the safety aspects associated with these drugs when used to treat different diseases published in Expert Opinion on Drug Safety in the April issue. 

Claudiu Supuran picks Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013) by Sergio Valente & Antonello Mai as the highlight of the April issue. Read it FREE here.

Fungal infections represent a worldwide health problem and resistance to many of the clinically used drugs is reported more and more frequently. The review presents a discussion of the patent literature in the last three years, with a focus on compounds with broad efficacy, good pharmacologic profiles, absence of drug-drug interactions, etc. Click HERE to read.

First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!

The Editor-in-Chief of Expert Opinion on Therapeutic Patents, Claudiu Supuran, has chosen Novel thiazole derivatives: a patent review (2008-2012; Part 1) by Alberto Leoni, Alessandra Locatelli, Rita Morigi & Mirella Rambaldi as his Editor’s Pick for the February issue.

Professor Claudiu Supuran, Editor-in-Chief of Expert Opinion on Therapeutic Patents, has chosen Tubulin inhibitors: a patent review by Yi-Min Liu , Hsiao-Ling Chen , Hsueh-Yun Lee & Jing-Ping Liou as his Editor’s Pick for the January issue.

The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!

Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013

If you want to know more about Rho kinase inhibitors, look no further! Expert Opinion on Therapeutic Patents and Expert Opinion on Investigational Drugs have both recently posted articles on these compounds from different points of view.

Editor-in-Chief of Expert Opinion on Therapeutic Patents, Prof. Claudiu Supuran, chooses Inhibitors of cathepsin G: a patent review (2005 to present) by Paulina Kosikowska & Adam Lesner as his Editor’s Pick for the December issue.

Editor-in-Chief of Expert Opinion on Therapeutic Patents, Professor Claudiu Supuran, has chosen AT1 antagonists: a patent review (2008-2012) by Thomas Mavromoustakos, George Agelis & Serdar Durdagi as his Editor’s Pick for the November issue.

Editor-in-Chief, Prof. Claudiu Supuran, has chosen Estrogen receptor ligands: a patent review update by Ilaria Paterni, Simone Bertini, Carlotta Granchi, Marco Macchia & Filippo Minutolo as his Editor’s Pick for the October 2013 issue of Expert Opinion on Therapeutic Patents!

Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012) by Hideaki Fujii, Toshihiro Takahashi and Hiroshi Nagase

PDE4 inhibitors: a review of current developments (2010-2012) by Amadeu Gavaldà & Richard S Roberts

European patent for Pfizer’s Viagra expires – 21st June 2013

Despite extending the patent protection on Viagra (sildenafil) in the US until 2020, Pfizer now has to face the effects of patent expiration in the UK and other countries in Europe. 

5-Lipoxygenase inhibitors: a review of recent patents (2010 – 2012) by Bettina Hofmann & Dieter Steinhilber

PARP INHIBITORS IN CANCER THERAPY: AN UPDATE by Gianluca Papeo, Elena Casale, Alessia Montagnoli, and Alessandra Cirla

Novel 1H-1,2,3-, 2H-1,2,3-, 1H-1,2,4- and 4H-1,2,4-triazole derivatives: a patent review (2008-2011) by Vitor F Ferreira et al

Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012) by Daniel Flesch, Daniel Merk, Christina Lamers & Manfred Schubert-Zsilavecz is the article pick of the month from Editor-in-Chief Claudiu Supuran.

Sulfatase inhibitors: a patent review by Spencer J Williams is our Editor’s pick from Claudiu T. Supuran for the January 2013 issue of Expert Opinion on Therapeutic Patents.

Patented TGR5 modulators: a review (2006 – present) by Antimo Gioiello, Emiliano Rosatelli, Roberto Nuti, Antonio Macchiarulo & Roberto Pellicciari is the pick of the November issue from our Editor-in-Chief Claudiu Supuran.

Flavonoids in the therapy and prophylaxis of flu: a patent review by Sônia S Costa, José Nelson S S Couceiro, Isabel Cristina V Silva, David do C Malvar, Marcela A S Coutinho, Luiza Maria M Camargo, Michelle F Muzitano & Frederico A Vanderlinde is our Editor’s pick of the month for the October issue.

Novel pharmacological modulators of autophagy and therapeutic prospects by Bischoff, Josset and Dumont is the Editor’s pick for September in EOTT.

This interesting paper reviews the scientific and patent literature of the last 4 years (2008-2012) in the field of autophagy and modulators (inhibitors or enhancers) of this phenomenon.

In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.

“Compositions and methods for treatment of Parkinson’s disease: a patent evaluation of WO2011/102847A1” Valerio Chiurchiù, Mauro Maccarrone, & Antonio Orlacchio

An evaluation of the application: WO2011/102847A1, which discusses novel and interesting methods to treat Parkinson’s disease (PD).  The invention under discussion centres on a method for treating or preventing PD by increasing the level of at least one protein involved in an autoregulatory pathway, which is fundamental during mDA neurons differentiation.

For access to the article summary, please click here.

“Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)” Maria Altamura

In this article, Dr Maria Altamura discusses the potential of Tachykinin NK2 receptor antagonists in the treatment of various gastrointestinal, genitourinary and CNS diseases. An overview of patenting activity in the last 5 years is provided, including an evaluation of the patents novelty, proposed indications and clinical studies. Furthermore, patents claiming new therapeutic indications are included in a dedicated section.

For access to the article summary, please click here.

This month, Expert Opinion has recorded a Podcast with Dr Philip Carpino from Pfizer. Dr Carpino discussed his paper entitled ‘Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature’ published in the December 2010 issue of Expert Opinion on Therapeutic Patents. Dr Carpino describes the competitive landscape in the area and the pharmacological targets that pharmaceutical companies and academic institutions are focusing on. The pharmaceutical industry has responded to the diabetes crisis by investigating multiple targets and many different pathways and it remains to be seen if this flurry of patent activity has lead to more compounds in clinical development.